Morphosis Inc.

Morphosis Inc., a small disadvantaged business based in Berkeley, California, develops biometric authentication and neurometric security technology for federal health and research agencies as a prime contractor under small-business set-asides. The company operates exclusively as a prime (100% of recent awards) with no subcontracting footprint, focusing narrowly on research and development in authentication systems for healthcare and secure human-computer interaction.

Morphosis holds three federal awards across two agencies totaling $4.1 million in combined potential value. The National Institutes of Health funds two awards: a $3.5 million Phase II definitive contract for base work running through February 2029 (awarded August 27, 2026, under total small business set-aside) and a $600 thousand SBIR Phase I definitive contract for neurometric authentication in healthcare environments (awarded September 12, 2024, under total small business set-aside). The National Science Foundation funded a $275 thousand Technology, Innovation, and Partnerships project grant (CFDA 47.084) awarded September 1, 2024, for continuous identity verification via wearable neural interfaces; the NSF award period ran through February 28, 2025. All three awards represent early-stage innovation work, with the NIH Phase II contract as the only effort extending beyond 2025.

Customer concentration is constrained by the vendor's narrow portfolio: NIH accounts for two awards and $4.1 million in combined potential value (100% coverage across the award count and potential-value rankings), while NSF holds the third award. The vendor has worked with no other federal agencies in the available data. Activity is nascent — two awards in 2024 and one in 2026 — with no prior award history visible in the source. The NSF Phase I award has already completed (ultimate completion February 28, 2025), while the NIH Phase I contract completes November 12, 2025, leaving the Phase II effort as the only active or future-committed work.

Service Contract Inventory reporting shows $500 thousand in SCI-reportable invoiced revenue across FY2024–FY2025 ($100 thousand in FY2024, $400 thousand in FY2025), with 2.7 FTEs assigned to the FY2025 prime contract. SCI captures a subset of federal services contracts above the $150,000 threshold and excludes goods, products, and classified work; Morphosis's full federal footprint is narrower than its enterprise total. The vendor performs all delivery with internal labor (0% sub-hours share across SCI-reportable prime contracts) and holds no named subcontractor relationships in the available award data. Morphosis's capability portfolio centers on biometric sensing, neural interface integration, and authentication system development for cybersecurity and healthcare access control applications, with all work rooted in SBIR innovation phases and NSF research sponsorship rather than established federal service lines.